# Associations Between Dietary Intakes of Omega-3 Fatty Acids, Blood Levels, and Pain Interference in People with Migraine: A Path Analysis of Randomized Trial Data

**Authors:** Jinyoung Park, Zachary O. Kadro, Gilson D. Honvoh, Anthony F. Domeniciello, Christopher E. Ramsden, Keturah R. Faurot, Vanessa E. Miller

PMC · DOI: 10.3390/nu18010003 · Nutrients · 2025-12-19

## TL;DR

This study found that higher blood levels of omega-3 fatty acids EPA and DHA are linked to reduced pain interference in migraine patients.

## Contribution

The study identifies an indirect pathway from dietary omega-3 intake to reduced migraine pain via blood levels of EPA and DHA.

## Key findings

- Higher blood EPA levels at 16 weeks were strongly associated with lower pain interference.
- DHA levels also showed a weaker but significant association with reduced pain interference.
- Path models confirmed a good fit for both EPA and DHA in explaining pain interference.

## Abstract

Background/Objectives: Increasing evidence supports the hypothesis that dietary intervention can improve pain among individuals with headaches, including migraine, a highly prevalent condition that can be disabling. Non-pharmacologic treatments for migraine are particularly attractive. In this secondary analysis of 182 participants enrolled in a randomized controlled trial of a dietary intervention designed to increase omega-3 (n-3) compared with a control diet, we examined the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both thought to decrease inflammatory processes. Methods: Path models with two time points (baseline and 16 weeks after randomization), were used to test the relationships between exposures of n-3 blood levels and self-reported dietary intake on outcomes of pain interference using the PROMIS pain interference scale and the Headache Impact Test (HIT-6). Model building was based on our published conceptual model. Results: Good fit was demonstrated for both models (EPA model: CFI = 0.984, RMSEA = 0.039, and SRMR = 0.045; DHA model: CFI = 0.981, RMSEA = 0.040, and SRMR = 0.040). Both EPA and DHA in the blood at 16 weeks were associated with lower levels of pain interference, but the effect for EPA was stronger (B = −0.56, p < 0.001 for EPA, and B = −0.43, p = 0.057 for DHA). Conclusions: Our findings are consistent with an indirect pathway linking diet to pain interference through blood levels of EPA and DHA in migraine.

## Linked entities

- **Chemicals:** omega-3 fatty acids (PubChem CID 56842239), eicosapentaenoic acid (PubChem CID 5282847), docosahexaenoic acid (PubChem CID 445580)
- **Diseases:** migraine (MONDO:0005277)

## Full-text entities

- **Diseases:** Headache (MESH:D006261), Migraine (MESH:D008881), inflammatory (MESH:D007249), Pain Interference (MESH:D010146)
- **Chemicals:** DHA (MESH:D004281), Omega-3 Fatty Acids (MESH:D015525), EPA (MESH:D015118)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12787831/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12787831/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12787831/full.md

---
Source: https://tomesphere.com/paper/PMC12787831